Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.

Urogen Pharma (NASDAQ: URGN ... This compares to the stock's 32.5% gain over the past four weeks.

LG H&H Co. Ltd. 0.17% ₩4.7T LG H&H Co. Ltd. Pfd. Series 1 0.61% ₩4.7T ...